ContraVir Pharmaceuticals (NASDAQ: CTRV) is developing targeted antiviral therapies with two drug candidates in clinical studies. The first drug candidate, FV-100, is now in phase 3 trials. It is being developed for the treatment of herpes zoster, or shingles, and … Continue reading →

Aytu BioScience, Inc. (OTC: AYTU) is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. Aytu is initially concentrating on prostate cancer, male sexual dysfunction and male infertility and plans to expand into … Continue reading →

Ceapro, Inc. (OTC: CRPOF) is a Canadian biotechnology company with headquarters in Edmonton, Alberta. Through the use of proprietary technology and renewable and sustainable resources, Ceapro is focused on becoming a global leader in developing and commercializing functionally active ingredients … Continue reading →

NephroGenex, Inc. (NASDAQ: NRX) is an innovator in the development of drugs to treat kidney disease with a first indication in diabetic nephropathy. It has been pioneering the development of PYRIDORIN (pyridoxamine dihydrochloride), a late stage compound to treat the … Continue reading →

Bio-Path Holdings, Inc. (NASDAQ: BPTH) is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systematically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. The company’s … Continue reading →

Benitec Biopharma (NASDAQ: BNTC) has developed a breakthrough platform for treating human diseases called DNA-directed RNAi (ddRNAi). Unlike other RNAi-based technologies, ddRNAi effects lasting change in target cells, leading to long term benefits and, potentially, a cure. The company thus … Continue reading →

Navidea Biopharmaceuticals (NASDAQ: NAVB) envisions a world where disease can be precisely identified and treated. Navidea is a leader in precision medicine with products  designed to help identify the sites and pathways of  undetected disease and enable better diagnostic accuracy, … Continue reading →

Biosig Technologies (OTC: BSGM) is a development stage medical device company that engages in developing technology platforms for the purposes of reducing noise from cardiac recordings during electrophysiology studies. The company’s main product under development is PURE (Precise Uninterrupted Real-time … Continue reading →

DelMar Pharmaceuticals, Inc. (OTC: DMPI) is a clinical and commercial stage drug development company with a focus on the treatment of cancer. The company is in the midst of conducting clinical trials in the U.S. with its product candidate, VAL-083, … Continue reading →

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) is focused on the invention and development of novel pharmaceutical products for medical conditions that it believes have broad societal impact, and that are not well served by currently available therapies. Tonix’s Tonmya™ is currently … Continue reading →